Decoding the potential link between Covid-19 and mucormycosis: Literature review
Descifrando el vínculo potencial entre la COVID-19 y la Mucormicosis: Revisión de la literatura
dc.creator | Mounika, S | |
dc.creator | Vasanthi, V | |
dc.creator | Divya, Bose | |
dc.creator | Narayan, Madhu | |
dc.creator | Kumar, A Ramesh | |
dc.creator | Rajkumar, K | |
dc.date | 2024-12-31 | |
dc.date.accessioned | 2025-05-19T19:23:08Z | |
dc.date.available | 2025-05-19T19:23:08Z | |
dc.identifier | https://revistas.udec.cl/index.php/journal_of_oral_research/article/view/19681 | |
dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/253040 | |
dc.description | Background: Mucorales, the causative agent of mu-cormycosis, is a life-threatening fungal infection that pri-marily affects immunocompromised hosts. This condition is becoming more severe during the current COVID-19 pandemic. The objective is to decipher the link between mucormycosis, steroids, and the associated co-morbidities of COVID-associated mucormycosis (CAM). This study is focussed on assessing the various aspects of COVID related mucormycosis. Aim: To systematically review the reported cases of CAM, clinical presentation with steroid therapy and associated comorbidities. Materials and Methods: MeSH terms like mucor-mycosis, diabetes, SARS-CoV-2 infection, sinus, orbit, and palate were searched in the PUBMED and Google Scholar databases, and 20 case reports and case series were identified.Results: We found that India had the highest number of cases (60%), 55% of the infected patients were male, 65% had a history of diabetes and the associated risk factor was uncontrolled diabetes (90%). The common clinical presentation among the cases was noted to be necrosis and swelling, with 55% of the cases reported to be rhino orbital mucormycosis. In most of the cases cytological and histological examination had been performed with haematoxylin & eosin, KOH, lactophenol cotton blue, and special stains such as PAS and GMS had been used in few cases along with culture in Sabouraud dextrose agar. Regarding treatment, 85% of the cases were treated with amphotericin B and in 15% of cases a combination of amphotericin B and posaconazole was employed. The rate of mortality reported was estimated to be 25%. Conclusion: COVID-19 infection poses a significant threat to diabetic patients, increasing their susceptibility to mucormycosis. Therefore, the careful use of steroids and routine monitoring are essential in preventing this invasive infection. | en-US |
dc.description | Antecedentes: Los Mucorales, agentes causantes de la mucormicosis, son una infección fúngica potencial-mente mortal que afecta principalmente a pacientes inmunocomprometidos. Esta condición se está volviendo más grave durante la actual pandemia de COVID-19. El objetivo de este estudio es descifrar el vínculo entre la mucormicosis, los esteroides y las comorbilidades asociadas con la Mucormicosis asociada a COVID (MAC). Este estudio se enfoca en evaluar diversos aspectos de la mucormicosis relacionada con la COVID-19. Objetivo: Revisar sistemáticamente los casos reportados de MAC, la presentación clínica con terapia con esteroides y las comorbilidades asociadas.Materiales y métodos: Se buscaron términos MeSH como Mucormicosis, diabetes, infección por SARS-CoV-2, sinuses, órbita y paladar en las bases de datos PUBMED y Google Scholar, obteniendo 20 informes de casos y series de casos reportados.Resultado: Encontramos que India tuvo el mayor número de casos (60%), el 55% de los pacientes infectados eran hombres, el 65% tenía antecedentes de diabetes y el factor de riesgo asociado era la diabetes no controlada (90%). La presentación clínica más común entre los casos observados fue necrosis e hinchazón, y el 55% de los casos fueron diagnosticados como mucormicosis rino-orbital. En la mayoría de los casos, se realizó un examen citológico e histológico utilizando hematoxilina-eosina, KOH, lactofenol algodón azul, y tinciones especiales como PAS y GMS, en algunos casos junto con cultivos en agar Sabouraud dextrosa. En cuanto al tratamiento, el 85% de los casos fueron tratados con anfotericina B y en el 15% de los casos se empleó una combinación de anfotericina B y posaconazol. La tasa de mortalidad reportada fue estimada en un 25%.Conclusión: La infección por COVID-19 representa una amenaza significativa para los pacientes diabéticos, aumentando su susceptibilidad a la mucormicosis. Por lo tanto, el uso cuidadoso de esteroides y la monitorización rutinaria son esenciales para prevenir esta infección invasiva. | es-ES |
dc.format | application/pdf | |
dc.language | eng | |
dc.publisher | Universidad de Concepción, Facultad de Odontología | es-ES |
dc.relation | https://revistas.udec.cl/index.php/journal_of_oral_research/article/view/19681/18123 | |
dc.rights | https://creativecommons.org/licenses/by/4.0 | es-ES |
dc.source | Journal of Oral Research; Vol. 13 (2024); 431-442 | en-US |
dc.source | Journal of Oral Research; Vol. 13 (2024); 431-442 | es-ES |
dc.source | Journal of Oral Research; v. 13 (2024); 431-442 | pt-BR |
dc.source | 0719-2479 | |
dc.source | 0719-2460 | |
dc.subject | Mucormicosis | es-ES |
dc.subject | COVID-19 | es-ES |
dc.subject | Esteroides; | es-ES |
dc.subject | Diabetes mellitus | es-ES |
dc.subject | Factores de riesgo | es-ES |
dc.subject | Mortalidad | es-ES |
dc.subject | Mortality | en-US |
dc.subject | Risk factors | en-US |
dc.subject | Diabetes mellitus | en-US |
dc.subject | Steroids | en-US |
dc.subject | COVID-19 | en-US |
dc.subject | Mucormycosis | en-US |
dc.title | Decoding the potential link between Covid-19 and mucormycosis: Literature review | en-US |
dc.title | Descifrando el vínculo potencial entre la COVID-19 y la Mucormicosis: Revisión de la literatura | es-ES |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.coverage | The authors declare that they have no conflict of interest in relation to the published results. | en-US |
This item appears in the following Collection(s)
-
Journal of Oral Research
[0-9]{4}